Creative Medical Technology Holdings (NASDAQ:CELZ) Full Year 2023 Results Key Financial Results Net loss: US$5.29m (loss narrowed by 48% from FY 2022) Earnings per share (EPS) missed analyst estimates by 2.2%. Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 17% growth forecast for the American Biotechs industry in the US.